Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 2,106,770 shares, a growth of 28.0% from the October 13th total of 1,645,486 shares. Currently, 6.8% of the company’s stock are sold short. Based on an average daily volume of 673,912 shares, the short-interest ratio is presently 3.1 days.

Rexahn Pharmaceuticals (NYSEAMERICAN RNN) opened at $2.12 on Thursday. Rexahn Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $7.10.

RNN has been the topic of several research analyst reports. HC Wainwright set a $20.00 price target on shares of Rexahn Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, September 11th. Seaport Global Securities reaffirmed a “buy” rating and set a $13.00 price target on shares of Rexahn Pharmaceuticals in a research report on Friday, October 6th. ValuEngine raised shares of Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 2nd. Zacks Investment Research raised shares of Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Wednesday, October 4th. Finally, Ifs Securities reaffirmed an “outperform” rating on shares of Rexahn Pharmaceuticals in a research report on Monday, August 7th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $13.65.

Hedge funds and other institutional investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Rexahn Pharmaceuticals in the third quarter worth about $119,000. Sabby Management LLC bought a new position in Rexahn Pharmaceuticals in the second quarter worth about $706,000. Susquehanna International Group LLP bought a new position in Rexahn Pharmaceuticals in the second quarter worth about $2,905,000. Finally, Renaissance Technologies LLC lifted its holdings in Rexahn Pharmaceuticals by 17.6% in the first quarter. Renaissance Technologies LLC now owns 5,758,391 shares of the company’s stock worth $2,937,000 after acquiring an additional 862,000 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/11/16/short-interest-in-rexahn-pharmaceuticals-inc-rnn-grows-by-28-0.html.

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

Receive News & Stock Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.